摘要 |
Disclosed is a lyophilized rapidly disintegrating solid dosage form, one embodiment of which comprises a thrombin receptor antagonist such as, formula (A), or a pharmaceutically acceptable salt or hydrate thereof, a polymer such as gelatin, and a matrix forming agent such as mannitol. Systems for effectively buffering the pre-lyophilized suspension are taught, along with methods of treating patients at risk for acute coronary syndrome by administering such a rapidly disintegrating solid dosage form. |
申请人 |
SCHERING CORPORATION;MONTEITH, DAVID;VELTRI, ENRICO, P.;DUGGIRALA, SRINIVAS;FALVO, MICHAEL, ANGELO;ERBEY II, JOHN, R.;FENG, KUNG-I;PAVLOVSKY, ANASTASIA;CHAWDRY, SULIMAN |
发明人 |
MONTEITH, DAVID;VELTRI, ENRICO, P.;DUGGIRALA, SRINIVAS;FALVO, MICHAEL, ANGELO;ERBEY II, JOHN, R.;FENG, KUNG-I;PAVLOVSKY, ANASTASIA;CHAWDRY, SULIMAN |